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Studies have shown high intussusception rates in Spain. We performed a hospital-based retrospective observational
study of the intussusception risk following rotavirus vaccinations among infants in Valencia, a region of Spain with an
annual birth cohort of approximately 48,000 children, during 2007–2011, using a self-controlled case series design. We
performed medical record review of all cases using Brighton Collaborations case deﬁnition and assessed the positive
predictive value (PPV) of the intussusception diagnosis code. Among 151 hospitalized cases discharged as
intussusception, we conﬁrmed 136 as Brighton Collaboration’s Levels 1 or 2, resulting in a PPV of 93% (95% CI:
87%–96%). Three conﬁrmed cases occurred within days 1–7 following the ﬁrst rotavirus vaccination. The incidence rate
ratio was 9.0 (95% CI: 0.9–86.5) (crude) and 4.7 (95% CI:0.3–74.1)(age adjusted). In this ﬁrst study in Europe, the
intussusception risk point estimate was comparable to other studies, although results were not statistically signiﬁcant,
maybe due to limited power. The high PPV found will facilitate implementation of a larger study without requiring
medical record review. Our ﬁnding of very few vaccinated cases despite a thorough 5-year investigation in a country
that, according to previous studies, may have a large background rate of intussusception is reassuring and should
contribute to deliberations about the need to include rotavirus vaccines in the ofﬁcial Spanish calendars.
Manuscript
Two oral live-attenuated rotavirus vaccines are currently available
in the global market: a monovalent human vaccine, Rotarix (Glax-
oSmithKline Biologicals, Rixensart, Belgium), indicated as a 2-dose
series in infants between the ages of 6–12 and 24 weeks,1 and a pen-
tavalent bovine-human reassortant vaccine, RotaTeq (Merck &
Co., Inc., West Point, PA, USA), indicated as a 3-dose series starting
at age 6–12 weeks and ending at age 32 weeks.2 Previously, an
observed association between Rotashield, the first licensed rotavirus
vaccine, and intussusception, caused its withdrawal from the US
market in 1999, only 9 months after licensure.3,4 The pre-licensure
clinical trials for both Rotarix (RV1) and RotaTeq (RV5),
designed to exclude an association with intussusception of similar
magnitude than that found for Rotashield, did not find an associa-
tion.5,6 However, after licensure, an increased risk, although of
much lower magnitude, was found with both vaccines in Australia,
Mexico, Brazil, and the United States.7-10
Both vaccines, RV1 and RV5, have been available in Spain
since August 2006 and January 2007, respectively. Rotavirus vac-
cines in Spain are not funded by the National Health System,
but are recommended by scientific societies and most pediatri-
cians, and paid for by parents. Due to the incidental finding of
circovirus DNA contamination affecting both vaccines, the Span-
ish Medicines Agency suspended RV5 distribution during June-
November 2010, and RV1 distribution since March 2010.11 As
of this publication, RV1 remains suspended in Spain.
Intussusception risk varies across population and regions,12
and some studies have shown high background rates of intussus-
ception in Spain;13,14 a potential association with rotavirus vacci-
nation could cause concern. Thus, our aim was to investigate
such association in the Valencia Region, Spain.
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SHORT REPORT
We performed a hospital-based retrospective observational
study during January 1, 2007 – December 31, 2011. Intussus-
ception risk following rotavirus vaccinations was assessed using a
self-controlled cases series (SCCS) design.15 The SCCS is a case-
only design that uses individuals who had the event of interest
during the study period; we applied the vaccinated cases only
SCCS approach, which uses only subjects who were exposed to a
rotavirus vaccine.16 Therefore, inference is done within individu-
als, and time-fixed confounders are controlled implicitly by
design. Unvaccinated individuals and individuals for which vacci-
nation status is unknown are excluded. The observation period
(follow-up person-time) for each individual is divided
in predefined risk and non-risk periods based on exposure.
Therefore, the event of interest falls either into a risk or a non-
risk period.15 In our case, the risk periods were defined as days
1–7, and 8–21, post-vaccination, following each dose of any rota-
virus vaccine. The comparison (non-risk) period was days 22–42
following each dose. The study included assessment of the posi-
tive predictive value (PPV) of the intussusception code used in
the Spanish hospital discharge database, CMBD.17
Almost all the Valencia Region population (>98%) is covered
by the public health system,18 and all users have a unique identi-
fication number that allows linking all health care databases and
all medical records.
Potential intussusception cases among resident infants aged
6–42 weeks, irrespective of their rotavirus vaccination status, were
identified from CMBD through the ICD-9-CM code 560.0 in
any diagnosis position. A review of hospitalization and primary
care medical records of all potential cases was carried out using
the standardized Brighton Collaboration case definition for intus-
susception (see the Table S1 showing the Brighton criteria in the
Appendix).19 First intussusception episodes considered confirmed
(Brighton Level 1-Level 2) were included in the analyses. In our
study, the event date was the date of onset of symptoms.
The exposure of interest was vaccination with any dose of
rotavirus vaccines. Rotavirus vaccination status was obtained
from the regional vaccine information system, SIV.20 Lack of
information or inconsistencies were confirmed through phone
consultation with parents and verbal verification of the informa-
tion in the childs vaccination card.
Dose-specific incidence rate ratios (IRRs), and their 95% con-
fidence intervals (CI), were assessed to investigate the association
between confirmed intussusception cases and rotavirus vaccines
within the 2 predefined risk periods. The IRR is estimated by
within-individual comparisons of the incidence of the event of
interest in risk and control periods using person-time denomina-
tors. Given the strong confounding effect of age, analyses were
adjusted using, as reference, intussusception-hospitalized rates
by age in unvaccinated Valencia Regions children during
2001–2011.10 Specific rates by age were estimated using data from
CMBD and from the Spanish Statistical Office database (www.
ine.es); the pattern was modeled using spline function (Fig. 1).
The PPVs were assessed for the different categories of Brigh-
ton Collaboration case classification: (1) Level 1, (2) Level
1-Level 2, and (3) Levels 1-Level 2-Level 3. They were stratified
for discharge code position and calendar year.
All statistical tests were 2-sided. Statistical significance was
defined as p < 0.05. Analyses were performed using Stata/SE
13.1 (StataCorp LP Texas, USA), R 3.0.3 (Foundation for Statis-
tical Computing, Vienna, Austria), SAS 9.2 (SAS Institute, Inc.),
and SAS macros developed by Bart Spiessens.
The study was conducted according to the existing legislation
including the Good Epidemiological Practices (CIOMS 2009),
the Helsinki Declaration (Seoul 2008) and the Law 14/2007, of
3 July, on Biomedical Research, and was approved by the Ethics
Research Committee of the Direccion General de Salud Publica/
Centro Superior de Investigacion en Salud Publica, which pro-
vided a waiver to access personal information and contact
parents.
The Valencia Region has an annual birth cohort of around
48,000 infants among a total population of approximately
5,000,000 inhabitants. Within the population of interest, infants
aged 6 to 42 weeks discharged from hospitals of the Valencia
Regions public health system, 151 potential hospitalized-intus-
susception cases were identified after having excluded duplicate
episodes (children transferred to a reference hospital). Cases
occurred in 147 infants, since 4 infants (3%) had a second epi-
sode. Medical records were available for all cases. Among first
episodes, 125 cases (85.0%) were classified as Level 1, 11 (7.5%)
as Level 2, 2 (1.4%) as Level 3, 8 (5.4%) as Insufficient Evidence,
and one case (0.7%) was discarded. Of 136 confirmed intussus-
ception cases, 35 (26%) occurred in rotavirus-vaccinated children
(Fig. 2). Among them, 14 (40%), and 21 (60%) had received
RV1 and RV5, respectively.
The PPV of the diagnosis code for hospitalized intussuscep-
tion cases (any discharge diagnosis position) was 93% (95% CI:
87%–96%) for Level 1-Level 2 of diagnosis certainty. No differ-
ences by discharge diagnosis position or by calendar year were
found (Table 1).
Figure 1. Intussusception-hospitalized rates by age in unvaccinated
Valencia Regions children aged less than 12 months during 2001–2011.
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Three intussusception cases occurred within days 1–7 follow-
ing first dose of a rotavirus vaccine (two after RV1 and one after
RV5) resulting in a crude IRR point estimate of 9.0 (95%
CI: 0.9–86.5), and in an age-adjusted estimate of 4.7 (95%
CI:0.3–74.1) within this risk window. The number of cases
occurring within 1–7, 8–21, and 22–42 days following each
dose, and dose-specific IRRs are shown in Table 2.
In this first post-licensure analytical study of the intussuscep-
tion risk following rotavirus vaccination in Europe, we investi-
gated intussusception cases among infants discharged from all
Figure 2. Flowchart of hospitalized-intussusception cases.
Table 1. Positive predictive values according to The Brighton Collaboration case classiﬁcation by discharge code position, and by calendar year
Positive Predictive Values
Cases
n Level 1% (95% CI)
Level 1- Level 2
% (95% CI)
Level 1-Level 2-Level 3
% (95% CI)
Discharge code position
1st 148 86.5 (79.9–91.5) 93.2 (87.9–96.7) 94.6 (89.6–97.6)
1st or 2nd 149 86.6 (80.0–91.6) 93.3 (88.0–96.7) 94.6 (89.7–97.7)
Any 151 85.4 (78.8–90.6) 92.7 (87.3–96.3) 94.0 (89.0–97.2)
Calendar year1
2007 44 81.8 (67.3–91.8) 90.9 (78.3–97.5) 95.5 (84.5–99.4)
2008 30 86.7 (69.3–96.2) 93.3 (77.9–99.2) 93.3 (77.9–99.2)
2009 25 84.0 (63.9–95.5) 92.0 (74.0–99.0) 92.0 (74.0–99.0)
2010 28 89.3 (71.8–97.7) 92.9 (76.5–99.1) 92.9 (76.5–99.1)
2011 24 87.5 (67.6–97.3) 95.8 (78.9–99.9) 95.8 (78.9–99.9)
1Any diagnosis position.
Abbreviations: Positive Predictive Value (PPV); Conﬁdence interval (CI).
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hospitals of the Valencia Regions public health system, which
covers >98% of the approximately 5 million population of the
region, for a 5-year period. Therefore, it is unlikely that a signifi-
cant proportion of the total cases of intussusception would have
been seen in private hospitals. Also, vaccines administered in all
public and some private health centers are recorded in SIV,
regardless of their inclusion in the official immunization sched-
ule. A recent study has shown that, among all rotavirus vaccine
doses distributed during 2009–2012, most (86%) were registered
in SIV as administered in children aged less than one year.21
Nonetheless, because of these concerns, we chose a SCCS
approach restricted only to vaccinated cases. This method implic-
itly controls for time-fixed confounders, and, because of the
restriction to vaccinees, also minimizes potential misclassification
bias, and eliminates the need to address the healthy vaccinee
effect and the contraindication to vaccination issue found in
some studies. An additional strength of this study is that intussus-
ception diagnoses were confirmed through medical record review
of all potential cases hospitalized.
Our finding of an elevated intussusception risk point estimate
during the first week following administration of the first dose of
rotavirus vaccines was comparable in magnitude to estimates
from similar studies performed in the United States, Australia,
and Mexico.7-10 Despite having analyzed the whole population
of a large region for 5 years, our findings were not statistically sig-
nificant, maybe due to lack of study power. This is understand-
able given the rarity of intussusception and the low rotavirus
vaccine coverage in the region during the study period (full-
schedule coverage estimated for children aged under one year as
ranging between 24% to 49%, based on distributed vaccine
data). Because of the small size of the total vaccinated population,
and our need to evaluate rotavirus vaccine safety for the region
(regardless of specific vaccines used) both vaccines were evaluated
jointly. Our finding of very few vaccinated cases despite a thor-
ough multi-year investigation in a country which, according to
previous studies, may have a large background rate of intus-
susception,13,14 is reassuring, and provides information that
should contribute to deliberations about the need to include
rotavirus vaccines in the official Valencian and Spanish
calendars.
This study has also shown that a high quality investigation of
the safety of childhood vaccinations using Valencias healthcare
databases is possible. The high (93%) PPV found for a discharge
diagnosis of intussusception has opened the door to the imple-
mentation of a larger study without the need to perform medical
record reviews. Thus, we plan to continue the study for addi-
tional years, and invite also participation from other Spanish
regions. Moreover, following verification of the PPV of the dis-
charge diagnosis codes in candidate sites, the study could be
extended to include other European databases, thus gaining sub-
stantial power for the analysis of this rare event, even if vaccina-
tion coverage remains low. Such database integration will
substantially improve the capacity for timely post-licensure assess-
ments of the safety of any new vaccines introduced in Europe.
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